LifeStance Health Group (NASDAQ:LFST) to Repurchase $100.00 million in Outstanding Shares

LifeStance Health Group (NASDAQ:LFST) announced that its board has authorized a share repurchase program on Wednesday, February 25th, RTT News reports. The company plans to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 3.6% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.

LifeStance Health Group Trading Up 4.0%

NASDAQ:LFST opened at $7.24 on Friday. LifeStance Health Group has a 52 week low of $3.74 and a 52 week high of $8.30. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.58 and a current ratio of 1.58. The firm’s fifty day moving average is $7.13 and its 200-day moving average is $6.20. The firm has a market cap of $2.82 billion, a P/E ratio of 362.18 and a beta of 1.12.

LifeStance Health Group (NASDAQ:LFST) last released its earnings results on Wednesday, February 25th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.02). The firm had revenue of $382.20 million during the quarter, compared to analyst estimates of $378.51 million. LifeStance Health Group had a net margin of 0.68% and a return on equity of 0.66%. LifeStance Health Group’s quarterly revenue was up 17.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.01) EPS. Equities analysts expect that LifeStance Health Group will post -0.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on LFST. KeyCorp raised their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday. BTIG Research lifted their price target on LifeStance Health Group from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Wall Street Zen upgraded LifeStance Health Group from a “hold” rating to a “buy” rating in a report on Sunday, February 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LifeStance Health Group in a research note on Monday, December 29th. Finally, Barclays assumed coverage on shares of LifeStance Health Group in a report on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.67.

Insider Transactions at LifeStance Health Group

In related news, insider Ann Varanakis sold 50,000 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $6.90, for a total transaction of $345,000.00. Following the sale, the insider owned 315,610 shares in the company, valued at $2,177,709. This represents a 13.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert Bessler sold 119,942 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $7.04, for a total value of $844,391.68. Following the sale, the director directly owned 1,318,983 shares of the company’s stock, valued at $9,285,640.32. This represents a 8.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 270,086 shares of company stock worth $1,891,264 over the last three months. 3.20% of the stock is owned by company insiders.

Key Stories Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Board authorizes a $100 million share repurchase (up to ~3.6% of shares), signaling management thinks the stock is undervalued and reducing float. LifeStance to Repurchase $100M
• Positive Sentiment: Multiple firms raised price targets and ratings (UBS to $12, Canaccord to $10, KeyCorp to $9), increasing visible upside and buy-side interest. Analyst Price Target Raises
• Positive Sentiment: Company set 2026 revenue target of $1.615B–$1.655B and highlighted progress on AI and EHR initiatives that can drive scale and margin expansion over time. 2026 Revenue Target & Initiatives
• Neutral Sentiment: Coverage roundup: several analysts reviewed the stock following the quarter; the market reaction depends on whether upgrades translate into sustained buy-side flows. 6 Analysts Assess LFST
• Negative Sentiment: Q4 EPS missed expectations (reported ~$0.03 vs. ~$0.06 expected) despite revenue beating estimates; EPS weakness and still-modest margins remain near-term headwinds. Q4 2025 Earnings Highlights
• Negative Sentiment: Selling stockholders filed a secondary offering of 25M shares (company not raising proceeds), creating potential supply/overhang that can cap near-term upside. Secondary Public Offering

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.